EMEA-001407-PIP02-15-M05
Key facts
Invented name |
Opdivo
|
Active substance |
nivolumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0237/2021
|
PIP number |
EMEA-001407-PIP02-15-M05
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|